Metformin (MET) is the first-line drug for treating type 2 diabetes mellitus (T2DM). However, MET increases blood lactate levels in patients with T2DM. Lactate possesses proinflammatory properties and causes insulin resistance (IR). Oxamate (OXA), a lactate dehydrogenase inhibitor, can decrease tissue lactate production and blood lactate levels. This study was conducted to examine the effects of the combination of OXA and MET on inflammation, and IR in diabetic db/db mice. Supplementation of OXA to MET led to lowered tissue lactate production and serum lactate levels compared to MET alone, accompanied with further decreased tissue and blood levels of pro-inflammatory cytokines, along with better insulin sensitivity, beta-cell mass, and glycemic control in diabetic db/db mice. These results show that OXA enhances the anti-inflammatory and insulin-sensitizing effects of MET through the inhibition of tissue lactate production in db/db mice.

Keywords:
Oxamate, Metformin, Inflammation, Insulin resistance, db/db mice
1.
Rena G, Pearson ER, Sakamoto K: Molecular mechanism of action of metformin: old or new insights? Diabetologia 2013;56:1898-1906.
2.
An H, He L: Current understanding of metformin effect on the control of hyperglycemia in diabetes. J Endocrinol 2016;228:R97-R106.
3.
Hattori Y, Suzukim K, Hattori S, Kasai K: Metformin inhibits cytokine-induced nuclear factor kB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006;47:1183-1188.
4.
Huang NL, Chiang SH, Hsueh CH, Liang YJ, Chen YJ, Lai LP: Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int J Cardiol 2009;134:169-175.
5.
Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, et al: Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006;26:611-617.
6.
Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK: Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014;312:2668-2675.
7.
Adeva-Andany M, López-Ojén M, Funcasta-Calderón R, Ameneiros-Rodríguez E, Donapetry-García C, Vila-Altesor M, et al: Comprehensive review on lactate metabolism in human health. Mitochondrion 2014;17:76-100.
8.
Pujari KN, Jadkar SP, Belwalkar GJ: Lactate dehydrogenase levels in leukemias. Int J Pharma Bio Sci 2012;3:B454-B459.
9.
Zheng J, Woo SL, Hu X, Botchlett R, Chen L, Huo Y, et al: Metformin and metabolic diseases: a focus on hepatic aspects. Front Med 2015;9:173-186.
10.
Mueller WM, Stanhope KL, Gregoire F, Evans JL, Havel PJ: Effects of metformin and vanadium on leptin secretion from cultured rat adipocytes. Obes Res 2000;8:530-539.
11.
Jansson PA, Gudbjörnsdóttir HS, Andersson OK, Lönnroth PN: The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM. Diabetes Care 1996;19:160-164.
12.
Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, et al: Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Sci Rep 2016;6:18673.
13.
Alves MG, Martins AD, Vaz CV, Correia S, Moreira PI, Oliveira PF, et al: Metformin and male reproduction: effects on Sertoli cell metabolism. Br J Pharmacol 2014;171:1033-1042.
14.
Choi CS, Kim YB, Lee FN, Zabolotny JM, Kahn BB, Youn JH: Lactate induces insulin resistance in skeletal muscle by suppressing glycolysis and impairing insulin signaling. Am J Physiol Endocrinol Metab 2002;283:E233-E240.
15.
Lombardi AM, Fabris R, Bassetto F, Serra R, Leturque A, Federspil G, et al: Hyperlactatemia reduces muscle glucose uptake and GLUT-4 mRNA while increasing (E1alpha) PDH gene expression in rat. Am J Physiol 1999;276:E922-E929.
16.
Hashimoto T, Hussien R, Oommen S, Gohil K, Brooks GA: Lactate sensitive transcription factor network in L6 cells: activation of MCT1 and mitochondrial biogenesis. FASEB J 2007;21:2602-2612.
17.
Samuvel DJ, Sundararaj KP, Nareika A, Lopes-Virella MF, Huang Y: Lactate boosts TLR4 signaling and NF-kappaB pathway-mediated gene transcription in macrophages via monocarboxylate transporters and MD-2 up-regulation. J Immunol 2009;182:2476-2484.
18.
Miao H, Chen L, Hao L, Zhang X, Chen Y, Ruan Z, et al: Stearic acid induces proinflammatory cytokine production partly through activation of lactate-HIF1α pathway in chondrocytes. Sci Rep 2015;5:13092.
19.
Emanuela F, Grazia M, Marco de R, Maria Paola L, Giorgio F, Marco B: Inflammation as a link between obesity and metabolic syndrome. J Nutr Metab 2012;2012:476380.
20.
Chen YD, Varasteh BB, Reaven GM: Plasma lactate concentration in obesity and type 2 diabetes. Diabetes Metab 1993;19:348-354.
21.
Ohlson LO, Larsson B, Björntorp P, Eriksson H, Svärdsudd K, Welin L, et al: Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 1988;31:798-805.
22.
Crawford SO, Hoogeveen RC, Brancati FL, Astor BC, Ballantyne CM, Schmidt MI, et al: Association of blood lactate with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study. Int J Epidemiol 2010;39:1647-1655.
23.
Juraschek SP, Shantha GP, Chu AY, Miller ER 3rd, Guallar E, Hoogeveen RC, et al: Lactate and risk of incident diabetes in a case-cohort of the atherosclerosis risk in communities (ARIC) study. PLoS One 2013;8:e55113.
24.
Ye W, Zheng Y, Zhang S, Yan L, Cheng H, Wu M: Oxamate improves glycemic control and insulin sensitivity via inhibition of tissue lactate production in db/db mice. PLoS One 2016;11:e0150303.
25.
Maagaard A, Holberg-Petersen M, Torjesen PA, Bruun JN, Kvale D: Insulin resistance is affected by increased levels of plasma lactate but not mitochondrial alterations in skeletal muscle in NRTI-exposed HIV-infected patients. HIV Clin Trials 2007;8:345-353.
26.
Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, et al: Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer 2010;9:33.
27.
Brinkmann C, Brixius K: Hyperlactatemia in type 2 diabetes: Can physical training help? J Diabetes Complications 2015;29:965-969.
28.
Végran F, Boidot R, Michiels C, Sonveaux P, Feron O: Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res 2011;71:2550-2260.
29.
Miller AM, Nolan MJ, Choi J, Koga T, Shen X, Yue BY, et al: Lactate treatment causes NF-kappaB activation and CD44 shedding in cultured trabecular meshwork cells. Invest Ophthalmol Vis Sci 2007;48:1615-1621.
30.
Haas R, Smith J, Rocher-Ros V, Nadkarni S, Montero-Melendez T, D'Acquisto F, et al: Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions. PLoS Biol 2015;13:e1002202.
31.
Lipina C, Macrae K, Hundal HS: Glucose availability and metabolism represent an important determinant of fatty-acid-induced insulin resistance and pro-inflammatory signalling in skeletal muscle. Diabet Med 2012;29:50.
32.
Chen S, Zhou J, Xi M, Jia Y, Wong Y, Zhao J, et al: Pharmacogenetic Variation and Metformin Response. Curr Drug Metab 2013;14:1070-1082.
33.
Hur KY, Lee MS: New mechanisms of metformin action: focusing on mitochondria and the gut. J Diabetes Investig 2015;6:600-609.
34.
Saisho Y: Metformin and inflammation: its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets 2015;15:196-205.
35.
Woo SL, Xu H, Li H, Zhao Y, Hu X, Zhao J, et al: Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. PLoS One 2014;9:e91111.
36.
Zeczycki TN, Maurice MS, Attwood PV: Inhibitors of pyruvate carboxylase. Open Enzym Inhib J 2010;3:8-26.
37.
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
38.
Fonseca VA: Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009;32(suppl 2):S151-S156.
39.
Granchi C, Bertini S, Macchia M, Minutolo F: Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem 2010;17:672-697.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.